Clinical Trials Browser

Terminated × Axitinib × Genitourinary × Clear all

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

Phase 2 Terminated

6 enrolled 11 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04458259 2025-08-28

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT03472560 2024-04-09

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Phase 2 Terminated

61 enrolled 26 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01649180 2021-08-12

PrE0801

Phase 2 Terminated

3 enrolled 7 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01806064 2020-10-19

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Phase 1/2 Terminated

173 enrolled 17 charts

Carcinoma, Renal Cell

NCT01599754 2019-09-20

ATLAS

Phase 3 Terminated

724 enrolled 17 charts

Carcinoma, Renal Cell

NCT01441414 2019-01-08

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled 10 charts

Carcinoma, Renal Cell

NCT02560012 2018-10-12

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2 Terminated

4 enrolled 3 charts

Carcinoma, Renal Cell